Reports
Sale
Overactive Bladder Market Size, Share, Growth, Analysis: By Drug Type: Anti Cholinergic Drug, Beta 3 Adrenergic Drugs, Botox, Neurostimulation, Intravesical Instillation; By Disease Type: Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Overactive Bladder Market Outlook
The overactive bladder market size is expected to grow at a CAGR of 2.52% during the forecast period of 2024-2032, driven by the rising prevalence and incidence of overactive bladder disorders and the introduction of novel treatment therapies across 8 major markets.
Overactive Bladder Market Overview
Overactive bladder (OAB) is a medical condition that causes the frequent and sudden urge to urinate. It can result in unintentional loss of urine (urgency incontinence). Overactive bladder syndrome shows a high prevalence rate of 17% in adults. In children, the incidence of overactive bladder is nearly 16.6%. However, similar incidence rates are witnessed in men and women. The rising cases of the condition is anticipated to augment the overactive bladder market growth in the forecast period.
The surge in drugs and medical device approvals by health regulatory agencies is likely to impact the market dynamics positively. In August 2023, the United States Food and Drug Administration (FDA) granted marketing approval to an implant called Revi System. The minimally invasive device, developed by Utah-based medical equipment supplier BlueWind Medical is aimed at treating overactive bladder. It works on neuromodulation therapy to manage symptoms of overactive bladder. The introduction of such novel treatment options in the market is likely to increase the overactive bladder market demand.
Several leading biopharmaceutical companies are actively investing in research and development activities to support the launch of potential treatment therapies for patients suffering from overactive bladder. Such strategic investments are anticipated to bolster the overactive bladder market growth. Moreover, the evolving preference for minimally invasive procedures such as neurostimulation will boost the market growth.
Overactive Bladder Market Trends
| Key Trends | Description |
| Drug and Medical Device Approvals | The surge in approvals by health regulatory authorities such as FDA is expected to influence the market value significantly. |
| Investments in Research and Development | Major biopharmaceutical companies are investing in research and development to support the launch of potential treatment therapies. |
| Minimally Invasive Procedures | Rising preference for minimally invasive procedures such as neurostimulation is poised to boost the market growth. |
| Rising Prevalence | The increasing prevalence of overactive bladder disorder and related conditions requiring medical intervention is driving the demand for advanced treatment options. |
Overactive Bladder Market Segmentation
Market Breakup by Drug Type
- Anti Cholinergic Drug
- Beta 3 Adrenergic Drugs
- Botox
- Neurostimulation
- Intravesical Instillation
The market segmentation by drug type includes anti-cholinergic drugs, beta-3 adrenergic drugs, botox, neurostimulation, and intravesical instillation. Catering to the diverse needs of the patients, this segmentation offers a variety of pharmacological and non-pharmacological options to treat and manage overactive bladder.
Market Breakup by Disease Type
- Idiopathic Bladder Overactivity
- Neurogenic Bladder Overactivity
The overactive bladder market share is segmented by disease type into idiopathic bladder overactivity and neurogenic bladder overactivity. Idiopathic bladder overactivity is characterized by overactive bladder symptoms without a known underlying cause whereas neurogenic bladder overactivity occurs as a result of underlying neurological conditions.
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
The distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and others. To ensure accessibility and availability of overactive bladder treatments, this segment offers various channels to cater to the growing patient base.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- o Italy
- o Spain
- o United Kingdom
- Japan
- India
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. North America dominates the regional market, with factors such as the presence of key market players along with a robust healthcare system. The rise in the launch of novel therapies in the region further bolsters the market growth.
Overactive Bladder Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- AbbVie Inc.
- Astellas Pharma Inc.
- Pfizer Inc.
- Sumitomo Pharma Co., Ltd
- Laborie
- Endo International PLC
- Hisamitsu Pharmaceutical Co., Inc.
- Medtronic
- Urovant Sciences
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Disease Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Overactive Bladder Market Report
- How will the market landscape evolve in the forecast period?
- What are the leading factors driving the growth of the market?
- What are the strategic investments being made by biopharmaceutical companies to develop novel drugs for overactive bladder treatment?
- Which diseases and conditions majorly contribute to the prevalence of the overactive bladder?
- What is the current incidence of overactive bladder, and how is it expected to impact the overactive bladder market size?
- Which drug type is predicted to dominate the overactive bladder market?
- What are the emerging trends in minimally invasive procedures for overactive bladder management, and how do they influence market dynamics?
- What are the challenges and constraints in the market?
- How do regulatory frameworks and reimbursement policies impact the market landscape?
- What are the key market segments and their respective growth trajectories?
- What are the competitive dynamics among key players in the market?
- What are the opportunities for growth and innovation in the overactive bladder market in the coming years?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Overactive Bladder Market Overview – 8 Major Markets
3.1 Overactive Bladder Market Historical Value (2017-2023)
3.2 Overactive Bladder Market Forecast Value (2024-2032)
4 Overactive Bladder Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Disease Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Disease Type Success Rate
6 Overactive Bladder Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
6.5 India Overactive Bladder Epidemiology Scenario and Forecast (2017-2032)
7 Overactive Bladder Market Landscape – 8 Major Markets
7.1 Overactive Bladder: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Overactive Bladder: Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Disease Type
8 Overactive Bladder Challenges and Unmet Needs
8.1 Disease Type Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Disease Type
10 Overactive Bladder Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Overactive Bladder Market Segmentation (2017-2032) - 8 Major Markets
11.1 Overactive Bladder Market (2017-2032) by Drug Type
11.1.1 Market Overview
11.1.2 Anti Cholinergic Drug
11.1.3 Beta 3 Adrenergic Drugs
11.1.4 Botox
11.1.5 Neurostimulation
11.1.6 Intravesical Instillation
11.2 Overactive Bladder Market (2017-2032) by Disease Type
11.2.1 Market Overview
11.2.2 Idiopathic Bladder Overactivity
11.2.3 Neurogenic Bladder Overactivity
11.3 Overactive Bladder Market (2017-2032) by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Pharmacy
11.3.5 Others
11.4 Overactive Bladder Market (2017-2032) by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
11.4.5 India
12 United States Overactive Bladder Market (2017-2032)
12.1 United States Overactive Bladder Market Historical Value (2017-2023)
12.2 United States Overactive Bladder Market Forecast Value (2024-2032)
12.3 United States Overactive Bladder Market (2017-2032) by Drug Type
12.3.1 Market Overview
12.3.2 Anti Cholinergic Drug
12.3.3 Beta 3 Adrenergic Drugs
12.3.4 Botox
12.3.5 Neurostimulation
12.3.6 Intravesical Instillation
12.4 United States Overactive Bladder Market (2017-2032) by Disease Type
12.4.1 Market Overview
12.4.2 Idiopathic Bladder Overactivity
12.4.3 Neurogenic Bladder Overactivity
13 EU-4 and United Kingdom Overactive Bladder Market (2017-2032)
13.1 EU-4 and United Kingdom Overactive Bladder Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Overactive Bladder Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Overactive Bladder Market Overview
13.4 EU-4 and United Kingdom Overactive Bladder Market (2017-2032) by Drug Type
13.4.1 Market Overview
13.4.2 Anti Cholinergic Drug
13.4.3 Beta 3 Adrenergic Drugs
13.4.4 Botox
13.4.5 Neurostimulation
13.4.6 Intravesical Instillation
13.5 EU-4 and United Kingdom Overactive Bladder Market (2017-2032) by Disease Type
13.5.1 Market Overview
13.5.2 Idiopathic Bladder Overactivity
13.5.3 Neurogenic Bladder Overactivity
14 Japan Overactive Bladder Market
14.1 Japan Overactive Bladder Market Historical Value (2017-2023)
14.2 Japan Overactive Bladder Market Forecast Value (2024-2032)
14.3 Japan Overactive Bladder Market (2017-2032) by Drug Type
14.3.1 Market Overview
14.3.2 Anti Cholinergic Drug
14.3.3 Beta 3 Adrenergic Drugs
14.3.4 Botox
14.3.5 Neurostimulation
14.3.6 Intravesical Instillation
14.4 Japan Overactive Bladder Market (2017-2032) by Disease Type
14.4.1 Market Overview
14.4.2 Idiopathic Bladder Overactivity
14.4.3 Neurogenic Bladder Overactivity
15 India Overactive Bladder Market
15.1 India Overactive Bladder Market (2017-2032) Historical Value (2017-2023)
15.2 India Overactive Bladder Market (2017-2032) Forecast Value (2024-2032)
15.3 India Overactive Bladder Market (2017-2032) by Drug Type
15.3.1 Market Overview
15.3.2 Anti Cholinergic Drug
15.3.3 Beta 3 Adrenergic Drugs
15.3.4 Botox
15.3.5 Neurostimulation
15.3.6 Intravesical Instillation
15.4 India Overactive Bladder Market (2017-2032) by Disease Type
15.4.1 Market Overview
15.4.2 Idiopathic Bladder Overactivity
15.4.3 Neurogenic Bladder Overactivity
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 India CDSCO
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Drug Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Drug Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Drug Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 AbbVie Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Astellas Pharma Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Pfizer Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Sumitomo Pharma Co., Ltd
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Laborie
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Endo International PLC
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Hisamitsu Pharmaceutical Co., Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Medtronic
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Urovant Sciences
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
List not exhaustive
23 Overactive Bladder Disease Type - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 2.52% during the forecast period of 2024-2032, driven by the rising incidence of overactive bladder disorders and the introduction of novel treatment therapies in the market.
The rise in novel product launches to treat overactive bladder syndrome is fuelling the demand for the market.
One of the significant trends in the market is the surge in drug and medical device approvals from health regulatory agencies such as the FDA. In August 2023, the United States Food and Drug Administration (FDA) offered marketing approval to BlueWind Medical's Revi System, an implant aimed to treat overactive bladder.
Based on the disease type, the market is segmented into idiopathic bladder overactivity and neurogenic bladder overactivity.
Based on the drug type, the market is segmented into anti-cholinergic drugs, beta-3 adrenergic drugs, Botox, neurostimulation, and intravesical instillation.
The distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.
Key players involved in the market are AbbVie Inc., Astellas Pharma Inc., Pfizer Inc., Sumitomo Pharma Co., Ltd, Laborie, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc., Medtronic, and Urovant Sciences.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER